Simris Group appoints experienced ADC clinical development leader Dr. András Strassz as Chief Medical Officer
Hammenhög, Sweden, October 29, 2026: Simris Group AB (publ) (“Simris” or the “Company”) announces the appointment of Dr. András Strassz as Chief Medical Officer (CMO). The appointment marks the next step in delivering the Company’s recently announced strategy as it builds the clinical expertise to advance its antibody-drug conjugate (ADC) programs.
